Peptide drugs can play in addressing unmet medical needs as an outstanding complement or preferable alternative to small molecule and biological drugs. EFL-701 is a stable and target-specific candidate to treat rare diseases with a long half-life and controlled release technology. We especially anticipate that EFL-701 would be the effective and well-tolerated drug for several skeletal-related diseases.